{
"TITLE": "BENCH TO BEDSIDE: NOVEL MECHANISMS IN DIABETES AND METABOLISM",
"YEAR": 2021,
"KEY FINDINGS": [
"AZP-3404, a peptide analog of IGFBP-2, induces weight loss and improves glucose metabolism in leptin-resistant db/db mice",
"BLNK/BTK are novel components in the NF-kappa B pathways of endothelial cells in diabetic condition",
"Canagliflozin and Linagliptin have different effects on inflammatory markers, CD34+ cell gene expression, and urine exosomes in type 2 diabetes subjects",
"Serum copper, selenium, and zinc concentrations are associated with different states of glucose tolerance"
],
"MAIN RESULT": "The papers present novel mechanisms and potential therapeutic targets for diabetes and metabolism, including the use of AZP-3404, BLNK/BTK, and Canagliflozin",
"HYPOTHESIS": "AZP-3404 may improve glucose metabolism by increasing insulin sensitivity and reducing inflammation in humans with type 2 diabetes",
"EXPERIMENT": {
"Title": "Investigating the effect of AZP-3404 on insulin sensitivity and inflammation in humans with type 2 diabetes",
"Equipment": ["Human subjects with type 2 diabetes", "AZP-3404", "Insulin sensitivity measurement device (e.g. euglycemic-hyperinsulinemic clamp)", "Inflammation biomarker measurement kit"],
"Steps": [
"Recruit human subjects with type 2 diabetes and randomize them to receive either AZP-3404 or placebo",
"Measure insulin sensitivity using a euglycemic-hyperinsulinemic clamp at baseline and after 12 weeks of treatment",
"Measure inflammation biomarkers (e.g. CRP, IL-6) at baseline and after 12 weeks of treatment",
"Compare insulin sensitivity and inflammation biomarkers between the AZP-3404 and placebo groups"
]
},
"KEYWORDS": [
"Diabetes",
"Metabolism",
"IGFBP-2",
"AZP-3404",
"Leptin resistance",
"NF-kappa B",
"Endothelial cells",
"Canagliflozin",
"Linagliptin",
"Type 2 diabetes"
]
}
